









Wegovy
(Semaglutide)
Wegovy Injection Cost Per Dosage
In Stock Dosages
Wegovy Injection Cost
£168.00
£189.00
£197.00
£247.00
£297.00
Start with a Consultation Form
Lose Up to 15% Body Weight with Wegovy, Backed by Clinical Studies
Getting started
Online Consultation Form
Get Approval
Order Wegovy
Ongoing monthly care
Access medication
Ongoing care and support

Achieve Your Ideal Weight Loss with Wegovy Injection
Select your current weight
0Weight you could lose (lbs):
0During a clinical trial of 68 weeks, Patients lost an average of 15% of their body weight by being on Wegovy, compared to 2.5% in the placebo group. In another study involving 17000 overweight patients, Wegovy demonstrated a 50% reduction in heart-related deaths.
Your Medically Approved Route to Wegovy

What is Wegovy?
Eligibility for Wegovy treatment
Wegovy (Semaglutide) is a prescription-based weight loss treatment approved in the UK for individuals who meet specific clinical criteria. It is typically prescribed for adults with a body mass index (BMI) of 30 or above, which falls within the obesity range. It may also be considered for those with a BMI of 27 or higher if they have at least one weight-related health condition, such as type 2 diabetes, cardiovascular disease, high blood pressure, or obstructive sleep apnoea.
Before initiating treatment, a healthcare professional must carry out a comprehensive clinical assessment to evaluate the patient’s medical history, risk factors, and current health status. This ensures the treatment is both appropriate and safe. Wegovy is designed to be used alongside lifestyle changes, such as dietary modifications and physical activity, for sustainable weight management.
However, Wegovy is not suitable for everyone. Individuals with a known allergy to Semaglutide or its components, as well as pregnant or breastfeeding women, should not use this medication due to potential safety concerns. All patients should consult a licensed clinician before starting treatment to confirm eligibility and receive ongoing medical supervision throughout the course of therapy.
Side effects of Wegovy injection
Side effects of Wegovy majorly depend on your body type and immune system. Like all other medications, it has some side effects, some more common than others.
Most Occurring side effects:
- Headache
- Loose or frequent bowel movements
- Constipation
- Nausea or vomiting
- Fatigue
- Abdominal discomfort
General side effects:
- Stomach discomfort or mild indigestion
- Light-headedness
- Belching
- Bloating
- Acid Reflux
- Hair loss
- Redness on the injected site
- Gallstones
- Gastritis
- Low blood sugar
- Altered taste perception
- Unusual skin sensitivity
Rare side effects
- Rapid or irregular heartbeat
- Delayed gastric emptying
- Shakiness or dizziness
- Yellowing of the eyes and skin
Serious side effects
Wegovy may cause grave side effects sometimes that require professional supervision immediately, such as:
- Diabetic retinopathy
- Inflamed pancreas
- Kidney or bladder stones
- Anaphylaxis
- Bone Fractures
- Bowel obstruction
How Wegovy differs from Mounjaro
While both Wegovy (semaglutide) and Mounjaro (tirzepatide) are injectable treatments used for weight management, they differ significantly in terms of their active ingredients, mechanism of action, and clinical efficacy.
Wegovy contains semaglutide, a GLP-1 receptor agonist. It works by mimicking the action of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate appetite, slows gastric emptying, and promotes satiety. By acting solely on the GLP-1 receptor, Wegovy effectively reduces hunger and calorie intake, making it a well-established option for weight loss and type 2 diabetes management.
Mounjaro, in contrast, contains tirzepatide, a dual agonist that targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism is thought to provide enhanced metabolic effects, offering greater improvements in insulin sensitivity, appetite regulation, and energy balance. Clinical trials suggest that Mounjaro may result in greater weight loss compared to single agonist therapies like Wegovy. The addition of GIP receptor activation is believed to amplify the overall therapeutic impact, particularly in individuals with obesity and insulin resistance.
Wegovy’s interaction with other medicines
Wegovy (Semaglutide) may interact with certain medications, which is why a thorough consultation with a licensed healthcare provider is essential prior to starting treatment. These interactions can affect the safety and effectiveness of both Wegovy and any concurrent medications, particularly those used for managing Type 2 diabetes.
One of the most notable interactions is with insulin and sulfonylureas, both of which are commonly prescribed to lower blood glucose. When taken in combination with Wegovy, these medications can increase the risk of hypoglycaemia (low blood sugar). To mitigate this, your doctor may adjust the dose of your insulin or sulfonylurea therapy while prescribing Wegovy to ensure a safe and balanced treatment plan.
Additionally, Wegovy should not be used in combination with other GLP-1 receptor agonists, such as Liraglutide (e.g., Saxenda) or Tirzepatide (Mounjaro). Using multiple GLP-1 based medications simultaneously does not enhance efficacy and may increase the risk of side effects or complications. Always inform your healthcare provider of all medications you are currently taking, including prescriptions, over-the-counter treatments, and supplements, to ensure safe prescribing practices.
What our patients say about Weight Loss Pharmacy



Frequently Asked Questions
How long should I stay on Wegovy for weight loss?
How does Wegovy work for weight loss?
Can I switch from Ozempic to Wegovy for weight loss?
How to speed up weight loss on Wegovy?
Did You Know?
Besides Wegovy’s weight loss benefits, the FDA further highlighted its cardiovascular benefits in March 2024, : Wegovy now also reduces the risk of heart attacks, strokes, and cardiovascular death in people who are overweight or obese with heart disease